PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria

Area of Science:

• Cardiovascular Disease Research
• Diabetes Mellitus Pathophysiology
• Hemostasis and Thrombosis

Background:

• Microalbuminuria is a known risk factor for cardiovascular disease (CVD) in patients with insulin-dependent diabetes mellitus (IDDM).
• The underlying pathophysiological mechanisms linking microalbuminuria to CVD remain unclear.
• Hemostatic system dysfunctions are being investigated as a potential contributing factor.

Purpose of the Study:

• To investigate whether hemostatic dysfunctions contribute to the association between microalbuminuria and CVD in IDDM patients.
• To compare levels of key hemostatic markers between microalbuminuric and normoalbuminuric IDDM patients.

Main Methods:

• Measurement of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), factor VII activity, plasma fibrinogen, and plasma endothelin-1 (ET-1).
• Comparison between 13 microalbuminuric (albumin excretion rate [AER] 20-200 µg/min) and 13 normoalbuminuric (AER < 20 µg/min) IDDM patients.
• Correlation analysis between hemostatic markers, AER, triglycerides, and factor VII.

Main Results:

• Microalbuminuric patients exhibited significantly higher PAI-1 activity, factor VII activity, and plasma fibrinogen levels compared to normoalbuminuric patients.
• No significant differences were observed in t-PA and ET-1 levels between the groups.
• Plasma fibrinogen correlated with AER, while triglycerides and factor VII correlated with PAI-1.

Conclusions:

• Microalbuminuria in IDDM is associated with a pro-coagulative and hypo-fibrinolytic state.
• These hemostatic dysfunctions may represent a key pathogenetic link between microalbuminuria and the increased risk of CVD in diabetic patients.
• Further research is warranted to elucidate the precise role of hemostasis in diabetic cardiovascular complications.